Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements : Exploratory Analyses From a Randomized, Controlled, Double-Blind Trial
Authors' conclusion
In this exploratory analysis of the LoDoCo2 trial, use of colchicine, 0.5 mg daily, was associated with a lower incidence of TKR and THR.
Study context
- Population
- Patients with chronic CAD
- Participants
- 5,522 patients
- Comparison
- Colchicine 0.5 mg daily vs placebo
- Colchicinen = 2,762
- Placebon = 2,760reference
- Primary endpoint
- Time to first total knee replacement (TKR) or total hip replacement (THR) since randomisation
- Follow-up
- Median 28.6 months
Methodological detailsexploratory analysis, double-blind, placebo-controlled, multicentre (43 centres, Australia and the Netherlands), intention-to-treat
- Exploratory analysis
- Double-blind
- Placebo-controlled
- Multicentre (43 centres, Australia and the Netherlands)
- Intention-to-treat
Primary result
As reported in the abstract
TKR or THR
Each group vs placeboIncidence rate difference, per 100 person-years (95% CI)
Colchicine
−0.40(−0.74 to −0.06)
Each group vs placeboHazard ratio (95% CI)
Colchicine
0.69(0.51–0.95)
Further findings
Sensitivity analyses (excluding baseline gout; omitting joint replacements in first 3 and 6 months)
- Similar results
Original publication
Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements : Exploratory Analyses From a Randomized, Controlled, Double-Blind Trial. Ann Intern Med. Published 30 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →